Cancer pathways' target not validated by clinical results

Nat Biotechnol. 1999 Mar;17(3):220. doi: 10.1038/6956.
No abstract available

Publication types

  • News

MeSH terms

  • Adenomatous Polyposis Coli / drug therapy
  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use*
  • Apoptosis / drug effects
  • Biotechnology / economics*
  • Clinical Trials as Topic / economics
  • Drug Industry / economics
  • Humans
  • Investments
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Sulindac / analogs & derivatives*
  • Sulindac / economics
  • Sulindac / therapeutic use

Substances

  • Antineoplastic Agents
  • Phosphodiesterase Inhibitors
  • Sulindac
  • sulindac sulfone